The Annals of Internal Medicine reports a metanalysis done to examine the optimal length of long-term osteoporosis drug treatment (ODT) and whether harms are associated with long-term ODT and while the ODT benefits are clear, the risk of rare harms and need for drug holidays is less certain. 
AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis.
A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).
In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"
A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.
Patients with RA, but without CV disease, who were treated with atorvastatin appeared to experience cardiovascular (CV) benefits similar to what has been observed in other populations, with a risk reduction of approximately one-third, according to a large, but prematurely terminated, trial in the
A panel of 10 sleep experts studied 20 common sleep myths and found little or no evidence in support of these beliefs.
Sleep issues are highly prevalent among US adults, but few admit to it or do anything to manage it.
JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.
A study of patients undergoing arthroscopic rotator cuff repair shows that corticosteroid injections in the month prior to surgery are associated with a significantly increased risk of surgical site infection.
A study from the British Society for Rheumatology Biologics Register (BSRBR-RA) demonstrates that polypharmacy is a predictor of lower treatment responses and more serious adverse events (SAEs) in rheumatoid arthritis (RA) patients.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
